BioMimetic Therapeutics, Inc. to Highlight Pre-Clinical and Clinical Activities at ORS and AAOS Meetings

BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced its schedule of events at the Orthopedic Research Society (ORS) and the American Academy of Orthopedic Surgeons (AAOS) meetings. These meetings are being held consecutively in Las Vegas, NV the week of February 22, 2009.

ORS Meeting; February 22 – February 25

The following posters will be presented at various times during the ORS meeting from February 22 – February 25 at the Venetian Sands EXPO Center Hall G:

• Poster #537 :: Release, Biopotency, and Stability of Recombinant Human Platelet-Derived Growth Factor-BB (rhPDGF-BB) from Freeze-Dried Bone Allograft (FDBA) for use in Tissue Repair and Regeneration
• Poster #597 :: Distribution, Mass Balance and Excretion of ¹²⁵Iodine-Labeled Recombinant Human Platelet-Derived Growth Factor-BB (rhPDGF-BB) Administered Intravenously to Rats
• Poster #1266 :: Evaluation of Four Collagen Matrices in Combination with Recombinant Human Platelet-Derived Growth Factor-BB (rhPDGF-BB) for Application in Rotator Cuff Repair

AAOS Meeting; February 25 – February 28

The following poster will be presented by BioMimetic clinical investigators at various times during the AAOS meeting from February 25 – February 28 at the Venetian Sands EXPO Center Hall D:

• Poster #213 :: Use of rhPDGF-BB for Foot and Ankle Fusions: A Prospective Study of 130 Fusions in 60 Patients

There will be one podium presentation during the AAOS Meeting featuring the use of rhPDGF-BB:

• Dr. Christopher DiGiovanni, BioMimetic’s lead U.S. clinical investigator, will present Bone Forming: Fusions during the AAOS Specialty Day Program. Dr. DiGiovanni’s presentation will take place on Saturday, February 28 at 2:00 p.m. PST at the Venetian Hotel in room 2401.

Additionally, BioMimetic will host a commercial exhibit booth #550 at the Venetian Sands EXPO Center Hall A between 9:00 a.m. – 5:00 p.m. PST from February 25 – February 27.

The Company will also host an investor and analyst meeting on Thursday, February 26 at 5:00 PST at Caesars Palace Las Vegas in the Augustus V Ballroom. The program will focus on opportunities in the growing foot and ankle surgery market and how the Company’s first orthopedic product candidate, Augment™ Bone Graft, will address clinical needs in this area. Management will also discuss corporate timelines and recent accomplishments. Contact BioMimetic’s corporate communications department for further information.

Investor Conference Presentation

In addition to the presentations being held at ORS and AAOS, Dr. Samuel Lynch, president and chief executive officer, will provide an update of corporate activities at the 2009 Canaccord Adams Musculoskeletal Conference. The presentation will take place at the University of Nevada Student Union Ballroom A in Las Vegas on Tuesday, February 24 at 1:00 p.m. PST. A live audio webcast of the presentation will be available at http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID=2550240 and on the Company’s website at www.biomimetics.com. The webcast will be accessible for a period of at least 30 days.

About BioMimetic

BioMimetic Therapeutics, Inc. is developing and commercializing bio-active recombinant protein-device combination products for the healing of musculoskeletal injuries and disease, including orthopedic, spine and sports injury applications. BioMimetic received marketing approval from the FDA for its first product, GEM 21S®, as a grafting material for bone and periodontal regeneration following completion of human clinical trials, which demonstrated the safety and efficacy of the rhPDGF-BB platform technology. Additionally, the Company has clinical trials ongoing with its product candidates Augment and Augment Injectable in multiple orthopedic bone healing indications including the treatment of foot and ankle fusions and the stimulation of healing of fractures of the wrist. The Company's previously approved product and lead product candidates all combine recombinant protein therapeutics with tissue specific scaffolds to actively stimulate tissue healing and regeneration.

GEM 21S® is the registered trademark of Luitpold Pharmaceuticals, Inc., who now owns and markets that product.

For further information, visit www.biomimetics.com or contact Kearstin Patterson, corporate communications, at 615-236-4419.